机构:[1]Department of Epilepsy Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.广东省中医院[2]Joint Laboratory of Chinese Herbal Glycoengineering and Testing Technology, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
The research was partially funded by grants from the Science and
Technology Development Fund, Macau SAR (File no. 034/2017/
A1 and 0017/2019/AKP), the Key-Area Research and
Development Program of Guangdong Province (File no.
2020B1111110006) and the University of Macau (File no.
MYRG2018-00083-ICMS/MYRG2019-00128-ICMS/CPG2022-
00014-ICMS).
第一作者机构:[1]Department of Epilepsy Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Xie Xuemin,Wu Youliang,Xie Haitao,et al.Polysaccharides, Next Potential Agent for the Treatment of Epilepsy?[J].FRONTIERS IN PHARMACOLOGY.2022,13:doi:10.3389/fphar.2022.790136.
APA:
Xie Xuemin,Wu Youliang,Xie Haitao,Wang Haiyan,Zhang Xiaojing...&Li Shaoping.(2022).Polysaccharides, Next Potential Agent for the Treatment of Epilepsy?.FRONTIERS IN PHARMACOLOGY,13,
MLA:
Xie Xuemin,et al."Polysaccharides, Next Potential Agent for the Treatment of Epilepsy?".FRONTIERS IN PHARMACOLOGY 13.(2022)